Technologies, Inc., 05850) on hES-qualified Matrigel (Corning, 354277)
coated plates. Cells were fed daily and split with ReLeSR (StemCell
Technologies, Inc., 05872) every 4–5 days in mTeSR1. H1 hESCs were
used to generate the targeted H1-AAVS1-TetOn-dCas9-KRAB hES cell line used
in this study. H1-AAVS1-TetOn-dCas9-KRAB hESCs were maintained similarly to
H1 hESCs.
HEK293T/17 cells (ATCC, CRL-11268) were maintained in DMEM (Thermo,
11965) supplemented with 10% FBS (Thermo, 10437), 1X GlutaMAX (Thermo,
35050), 1X non-essential amino acids (NEAA; Thermo, 11140), and 1X
Penicillin-Streptomycin (Corning, 30–002-CI). Cells were split with
0.25% Trypsin (Thermo, 25200) every 3–5 days.